| 1 |
Liu T, Sun Q, Gu J, Cen S, Zhang Q. Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105348] [Reference Citation Analysis]
|
| 2 |
Anwer A, Khan S, Amir F, Bhat SA, Azam SA, Hasan SK, Afroz M, Waseem R, Islam A, Parveen S, Kazim SN. Novel chimeric vectors harboring hepatitis B viral promoter and reporter gene demonstrated liver-specific significance. Future Virology. [DOI: 10.2217/fvl-2021-0259] [Reference Citation Analysis]
|
| 3 |
Shang J, Zhou J, Liu H, Ise RM, Tu Y, Ran J, Bai L, Tang H. Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients. BMC Infect Dis 2021;21:912. [PMID: 34488678 DOI: 10.1186/s12879-021-06554-1] [Reference Citation Analysis]
|
| 4 |
Chen R, Pei S, Chen Y, Tan L, Xue Y, Liu S, Huang Y, Fan X. Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. Front Med (Lausanne) 2021;8:701061. [PMID: 34307428 DOI: 10.3389/fmed.2021.701061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Suzuki F, Sezaki H, Hosaka T, Suzuki Y, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol Res 2021;51:503-8. [PMID: 33462964 DOI: 10.1111/hepr.13618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 6 |
Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, Wang Y. Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. J Clin Transl Hepatol 2021;9:143-8. [PMID: 34007795 DOI: 10.14218/JCTH.2020.00118] [Reference Citation Analysis]
|
| 7 |
Lee AR, Cho JY, Kim JC, Dezhbord M, Choo SY, Ahn CH, Kim NY, Shin JJ, Park S, Park ES, Won J, Kim DS, Lee JH, Kim KH. Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes. Int J Mol Sci 2021;22:1606. [PMID: 33562603 DOI: 10.3390/ijms22041606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Buti M, Roade L, Riveiro-Barciela M, Esteban R. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. Liver Int 2020;40 Suppl 1:15-21. [PMID: 32077604 DOI: 10.1111/liv.14367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 11 |
Entecavir/lamivudine/tenofovir-disoproxil-fumarate. Reactions Weekly 2020;1793:177-177. [DOI: 10.1007/s40278-020-75519-z] [Reference Citation Analysis]
|
| 12 |
Tang L, Kottilil S, Wilson E. Strategies to eliminate HBV infection: an update. Future Virology 2020;15:35-51. [DOI: 10.2217/fvl-2019-0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
